Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination

View ORCID ProfileDaisy Massey, Diana Berrent, View ORCID ProfileAthena Akrami, Gina Assaf, Hannah Davis, Karen Harris, Lisa McCorkell, View ORCID ProfileAaron M Ring, View ORCID ProfileWade L Schulz, Hannah Wei, View ORCID ProfileHarlan M Krumholz, View ORCID ProfileAkiko Iwasaki
doi: https://doi.org/10.1101/2021.07.21.21260391
Daisy Massey
1Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daisy Massey
Diana Berrent
2Survivor Corps
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Athena Akrami
3Sainsbury Wellcome Centre, University College London, London, UK
4Patient-Led Research Collaborative
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Athena Akrami
Gina Assaf
4Patient-Led Research Collaborative
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hannah Davis
4Patient-Led Research Collaborative
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Harris
4Patient-Led Research Collaborative
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa McCorkell
4Patient-Led Research Collaborative
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aaron M Ring
5Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Aaron M Ring
Wade L Schulz
1Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut
6Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wade L Schulz
Hannah Wei
4Patient-Led Research Collaborative
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harlan M Krumholz
1Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut
7Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
8Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Harlan M Krumholz
  • For correspondence: harlan.krumholz@yale.edu
Akiko Iwasaki
5Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
9Howard Hughes Medical Institute, Chevy Chase, MD,USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Akiko Iwasaki
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

As more people are vaccinated against SARS-CoV-2, many of those already infected are still suffering from Post-Acute Sequelae (PASC). Although there is no current treatment for PASC, reports from patients that the vaccine itself improves, and in some reports, worsens, PASC symptoms may lead to a deeper understanding of the causes of PASC symptoms and viable treatments. As such, we are conducting a study that measures the changes in PASC symptoms after vaccination. We are collecting baseline self-report and biospecimens for immune assays and then are following up with participants to collect the same data at 2-weeks, 6-weeks, and 12-weeks post-vaccination (first dose). Immune assays using blood specimens will include B-cell, T-cell, and myeloid cell panels; evaluation of T-cell responsiveness to SARS-CoV-2 peptides and antigen specific response; autoantibody screening (of IgG, IgM, and IgA antibodies that attack human proteins); and TCR sequencing and antigen mapping of CD8+ T-cells. Mucosal immunity will be measured using saliva specimens. The study aims to provide answers for people with PASC, especially regarding the causes of their symptoms and how the vaccine may affect them, and clues for PASC treatment.

Competing Interest Statement

Aaron Ring is an inventor of the REAP technology and founder of Seranova Bio, a company that will commercialize this technology. Akiko Iwasaki has served as a consultant to Adaptive Biotechnologies for a one-day meeting.

Clinical Trial

NCT04895189

Funding Statement

No external funding has been received.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Yale University Institutional Review Board, IRB 2000030423

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • This version revised for authorship.

Data Availability

This protocol and surveys are available to any researcher who requests them and can be found, in addition to MedRxiv, by emailing dorothy.massey@yale.edu.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted July 28, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination
Daisy Massey, Diana Berrent, Athena Akrami, Gina Assaf, Hannah Davis, Karen Harris, Lisa McCorkell, Aaron M Ring, Wade L Schulz, Hannah Wei, Harlan M Krumholz, Akiko Iwasaki
medRxiv 2021.07.21.21260391; doi: https://doi.org/10.1101/2021.07.21.21260391
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination
Daisy Massey, Diana Berrent, Athena Akrami, Gina Assaf, Hannah Davis, Karen Harris, Lisa McCorkell, Aaron M Ring, Wade L Schulz, Hannah Wei, Harlan M Krumholz, Akiko Iwasaki
medRxiv 2021.07.21.21260391; doi: https://doi.org/10.1101/2021.07.21.21260391

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Allergy and Immunology
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1093)
  • Dentistry and Oral Medicine (195)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (499)
  • Epidemiology (9757)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2303)
  • Geriatric Medicine (221)
  • Health Economics (462)
  • Health Informatics (1553)
  • Health Policy (732)
  • Health Systems and Quality Improvement (602)
  • Hematology (236)
  • HIV/AIDS (501)
  • Infectious Diseases (except HIV/AIDS) (11631)
  • Intensive Care and Critical Care Medicine (616)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2139)
  • Nursing (134)
  • Nutrition (335)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1172)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (309)
  • Pediatrics (694)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2172)
  • Public and Global Health (4645)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (455)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)